Genfit ADR (GNFT)

Genfit ADR Aktie (GNFT) Neueste Nachrichten

GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)

GlobeNewswire Inc.

GENFIT : Assemblée Générale Mixte du 22 mai 2024 — modalités de mise à disposition des documents préparatoires 

GlobeNewswire Inc.

GENFIT : Mise à disposition du Document d’Enregistrement Universel 2023 et du Rapport Annuel Form 20-F 2023

GlobeNewswire Inc.

GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update

GlobeNewswire Inc.

GENFIT Announces Revenues and Cash Position as of December 31, 2023

GlobeNewswire Inc.

GENFIT Announces 2024 Financial Calendar  

GlobeNewswire Inc.

GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial

GlobeNewswire Inc.

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

GlobeNewswire Inc.

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

GlobeNewswire Inc.

GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials

GlobeNewswire Inc.

GENFIT dévoile sa stratégie de développement dans l’ACLF lors de son « ACLF Day » organisé dans le cadre du congrès de l’AASLD The Liver Meeting® 2023

GlobeNewswire Inc.

GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

GlobeNewswire Inc.

GENFIT Reports Third Quarter 2023 Financial Information

GlobeNewswire Inc.